A photo of Punam Malik.

Director, Cincinnati Comprehensive Sickle Cell Center

Program Leader, Hematology and Gene Therapy Program

Marjory J. Johnson Chair, Gene and Cell Therapy

Professor, UC Department of Pediatrics

513-636-1333

513-636-1330

Board Certified

My Biography & Research

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders

Research Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology



Blog Posts

My Locations

My Education

MBBS: University of Delhi, New Delhi, India, 1985.

MD: University of Delhi, New Delhi, India, 1989.

MS: University of Maryland, Baltimore, MD, 1991.

Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.

My Publications

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Adair, JE; Androski, L; Bayigga, L; Bazira, D; Brandon, E; Dee, L; Deeks, S; Draz, M; Dubé, K; Dybul, M; et al. Gene Therapy. 2021.

Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Blood Cells, Molecules, and Diseases. 2021; 90.

Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. British Journal of Haematology. 2021; 194:617-625.

Cardiac pathophysiology in sickle cell disease. Gbotosho, OT; Taylor, M; Malik, P. Journal of Thrombosis and Thrombolysis. 2021; 52:248-259.

Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Pediatric Blood and Cancer. 2021; 68.

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Shrestha, A; Chi, M; Wagner, K; Malik, A; Korpik, J; Drake, A; Fulzele, K; Guichard, S; Malik, P. Blood Advances. 2021; 5:2385-2390.

Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. Cannon, P; Asokan, A; Czechowicz, A; Hammond, P; Kohn, DB; Lieber, A; Malik, P; Marks, P; Porteus, M; Verhoeyen, E; et al. Human Gene Therapy. 2021; 32:31-42.

Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al. Scientific Reports. 2020; 10.

Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. Niss, O; Lane, A; Asnani, MR; Yee, ME; Raj, A; Creary, S; Fitzhugh, C; Bodas, P; Saraf, SL; Sarnaik, S; et al. Blood Advances. 2020; 4:1501-1511.

Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Hetzel, M; Lopez-Rodriguez, E; Mucci, A; Ha Nguyen, AH; Suzuki, T; Shima, K; Buchegger, T; Dettmer, S; Rodt, T; Bankstahl, JP; et al. Haematologica. 2020; 105:1147-1157.